Mechanism and Strategies on Drug Resistance of Non-small Cell Lung Cancer to EGFR-TKI
-
摘要:
非小细胞肺癌（non-small cell lung cancer, NSCLC）占全部肺癌的80%，而NSCLC患者中有很大一部分在确诊时已经处于晚期。因此，对于晚期NSCLC的治疗也越来越受到人们的重视。既往晚期NSCLC的标准治疗为含铂双药联合化疗，但化疗药物对改善晚期NSCLC患者的生存期方面作用十分有限。随着医学分子生物学技术的发展和肺癌分子发病机制的研究，以表皮生长因子受体（epidermal growth factor receptor, EGFR）为靶点的分子靶向治疗在NSCLC的治疗中独领风骚。其代表药物为吉非替尼和厄洛替尼，这两种EGFR-TKIs已在全世界范围内得到认可并被广泛用于晚期NSCLC的治疗，尤其是对于EGFR敏感突变者。然而，经过一段时间（中位时间为6~12月）的治疗后，大部分患者会对EGFR-TKIs产生耐药，其耐药机制主要包括原发性和获得性耐药。本文综述了近年来NSCLC耐药机制的新进展及耐药后治疗的新策略。
Abstract:Non-small cell lung cancer (NSCLC) accounts for about 80% of all lung cancer. There is a great many NSCLC patients have been in advanced stage when diagnosed. As a result, people pay more attention to curing advanced NSCLC. The standard treatment to advanced NSCLC is platinum-based combined chemotherapy. Then exploring new therapies is extremely urgent to us. With the development of medical molecular biology techniques and the study of molecular pathogenesis of lung cancer, epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) such as gefitinib and erlotinib are becoming promising therapies for parts of patients with NSCLC. The compounds which target the EGFR play an important role in the treatment of the NSCLC. However, after a period of treatment (median time is 6 to 12 months), most patients will develop drug resistance to EGFR-TKIs. Intense research in these NSCLCs has identified two major mechanisms of resistance to TKIs: Primary and acquired resistances. The aim of this article was to summarize the development of the resistance mechanisms and new overcoming strategies on better treatment of drug resistant cancer cells in EGFR-mutant NSCLC.
-
Key words:
- EGFR /
- NSCLC /
- TKIs /
- Drug resistances /
- Mutant
-
-
[1] Torre LA, Bray F, Siegel RL, et al. Global cancer statistics, 2012[J]. CA Cancer J Clin, 2015, 65(2): 87-108. doi: 10.3322/caac.21262
[2] Yap TA, Gerlinger M, Futreal PA, et al. Intratumor heterogeneity: seeing the wood for the trees[J]. Sci Transl Med, 2012, 4(127): 127ps10.
[3] 丁丁. EGFR-TKI治疗前T790M突变对TKI治疗NSCLC的预测作用-荟萃分析[D]. 上海: 上海交通大学, 2014. Dingding, Predictive role of pretreatment EGFR T790M mutation on TKI therapy in ansclc patients-A Meta-analysis[D]. Shanghai: Shanghai JiaoTong University, 2014.
[4] Inukai M, Toyooka S, Ito S, et al. Presence of epidermal growth factor receptor gene T790M mutation as a minor clone in non-small cell lung cancer[J]. Cancer Res, 2006, 66(16): 7854-8. doi: 10.1158/0008-5472.CAN-06-1951
[5] Sos ML, Koker M, Weir BA, et al. PTEN loss contributes to erlotinib resistance in EGFR-mutant lung cancer by activation of Akt and EGFR[J]. Cancer Res, 2009, 69(8): 3256-61. doi: 10.1158/0008-5472.CAN-08-4055
[6] Engelman JA, Mukohara T, Zejnullahu K, et al. Allelic dilution obscures detection of a biologically significant resistance mutation in EGFR-amplified lung cancer[J]. J Clin Invest, 2006, 116(10): 2695-706. doi: 10.1172/JCI28656
[7] Sharma SV, Lee DY, Li B, et al. A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations[J]. Cell, 2010, 141(1): 69-80. doi: 10.1016/j.cell.2010.02.027
[8] Bivona TG, Hieronymus H, Parker J, et al. FAS and NF-κB signalling modulate dependence of lung cancers on mutant EGFR[J]. Nature, 2011, 471(7339): 523-6. doi: 10.1038/nature09870
[9] Nan J, Du Y, Chen X, et al. TPCA-1 is a direct dual inhibitor of STAT3 and NF-κB and regresses mutant EGFR-associated human non-small cell lung cancers[J]. Mol Cancer Ther, 2014, 13(3): 617-29. doi: 10.1158/1535-7163.MCT-13-0464
[10] Gong Y, Somwar R, Politi K, et al. Induction of BIM is essential for apoptosis triggered by EGFR kinase inhibitors in mutant EGFR-dependent lung adenocarcinomas[J]. PLoS Med, 2007, 4(10): e294. doi: 10.1371/journal.pmed.0040294
[11] Zhao M, Zhang Y, Cai W, et al. The Bim deletion polymorphism clinical profile and its relation with tyrosine kinase inhibitor resistance in Chinese patients with non-small cell lung cancer[J]. Cancer, 2014, 120(15): 2299-307. doi: 10.1002/cncr.28725
[12] Kim GW, Song JS, Choi CM, et al. Multiple resistant factors in lung cancer with primary resistance to EGFR-TK inhibitors confer poor survival[J]. Lung Cancer, 2015, 88(2): 139-46. doi: 10.1016/j.lungcan.2015.01.023
[13] Wu DW, Chen CY, Chu CL, et al. Paxillin confers resistance to tyrosine kinase inhibitors in EGFR-mutant lung cancers via modulating BIM and Mcl-1 protein stability[J]. Oncogene, 2016, 35(5): 621-30. doi: 10.1038/onc.2015.120
[14] Yu HA, Arcila ME, Rekhtman N, et al. Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers[J]. Clin Cancer Res, 2013, 19(8): 2240-7. doi: 10.1158/1078-0432.CCR-12-2246
[15] Hata AN, Niederst MJ, Archibald HL, et al. Tumor cells can follow distinct evolutionary paths to become resistant to epidermal growth factor receptor inhibition[J]. Nat Med, 2016, 22(3): 262-9. doi: 10.1038/nm.4040
[16] Hata A, Katakami N, Yoshioka H, et al. Spatiotemporal T790M Heterogeneity in Individual Patients with EGFR-Mutant Non-Small-Cell Lung Cancer after Acquired Resistance to EGFR-TKI[J]. J Thorac Oncol, 2015, 10(11): 1553-9. doi: 10.1097/JTO.0000000000000647
[17] Niederst MJ, Hu H, Mulvey HE, et al. The allelic context of the C797S mutation acquired upon treatment with third-generation EGFR inhibitors impacts sensitivity to subsequent treatment strategies[J]. Clin Cancer Res, 2015, 21(17): 3924-33. doi: 10.1158/1078-0432.CCR-15-0560
[18] Chabon JJ, Simmons AD, Lovejoy AF, et al. Circulating tumour DNA profiling reveals heterogeneity of EGFR inhibitor resistance mechanisms in lung cancer patients[J]. Nat Commun, 2016, 7: 11815. doi: 10.1038/ncomms11815
[19] Janjigian YY, Smit EF, Groen HJ, et al. Dual inhibition of EGFR with afatinib and cetuximab in kinase inhibitor-resistant EGFR-mutant lung cancer with and without T790M mutations[J]. Cancer Discov, 2014, 4(9): 1036-45. doi: 10.1158/2159-8290.CD-14-0326
[20] Lee JY, Sun JM, Lim SH, et al. A PhaseⅠb/Ⅱ Study of Afatinib in Combination with Nimotuzumab in Non-Small Cell Lung Cancer Patients with Acquired Resistance to Gefitinib or Erlotinib[J]. Clin Cancer Res, 2016, 22(9): 2139-45. doi: 10.1158/1078-0432.CCR-15-1653
[21] Ramalingam S, Yang JC, Lee CK, et al. LBA1_PR: Osimertinib as first-line treatment for EGFR mutation-positive advanced NSCLC: updated efficacy and safety results from two Phase Ⅰ expansion cohorts[J]. J Thorac Oncol, 2016, 11(4 Suppl): S152.
[22] Yang J, Ramalingam SS, Jänne PA, et al. LBA2_PR: Osimertinib (AZD9291) in pre-treated pts with T790M-positive advanced NSCLC: updated Phase 1(P1) and pooled Phase 2(P2) results[J]. J Thorac Oncol, 2016, 11(4 Suppl): S152-3. https://www.researchgate.net/publication/301333638_LBA2_PR_Osimertinib_AZD9291_in_pre-treated_pts_with_T790M-positive_advanced_NSCLC_Updated_phase_1_P1_and_pooled_phase_2_P2_results
[23] Sequist LV, Goldman JW, Wakelee HA, et al. Efficacy of rociletinib (CO-1686) in plasma-genotyped T790M-positive non-small cell lung cancer (NSCLC) patients (pts)[J]. J Clin Oncol, 2015, 33(15 suppl): abstr 8001.
[24] Wu YL, Kim DW, Felip E, et al. Phase (Ph) Ⅱ safety and efficacy results of a single-arm ph ib/Ⅱ study ofcapmatinib (INC280)+gefitinib in patients (pts) with EGFR-mutated (mut), cMET-positive (cMET+) non-small cell lung cancer (NSCLC)[J]. J Clin Oncol, 2016, 34(suppl): abstr 9020.
[25] Mok TS, Wu YL, Thongprasert S, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma[J]. N Engl J Med, 2009, 361(10): 947-57. doi: 10.1056/NEJMoa0810699
[26] Weickhardt AJ, Scheier B, Burke JM, et al. Local ablative therapy of oligoprogressive disease prolongs disease control by tyrosine kinase inhibitors in oncogene-addicted non-small-cell lung cancer[J]. J Thorac Oncol, 2012, 7(12): 1807-14. doi: 10.1097/JTO.0b013e3182745948
[27] Park K, Yu CJ, Kim SW, et al. First-Line Erlotinib Therapy Until and Beyond Response Evaluation Criteria in Solid Tumors Progression in Asian Patients With Epidermal Growth Factor Receptor Mutation-Positive Non-Small-Cell Lung Cancer: The ASPIRATION Study[J]. JAMA Oncol, 2016, 2(3): 305-12. doi: 10.1001/jamaoncol.2015.4921
[28] La Monica S, Madeddu D, Tiseo M, et al. Combination of Gefitinib and Pemetrexed Prevents the Acquisition of TKI Resistance in NSCLC Cell Lines Carrying EGFR-Activating Mutation[J]. J Thorac Oncol, 2016, 11(7): 1051-63. doi: 10.1016/j.jtho.2016.03.006
[29] Yang CH, Kim DW, Kim SW, et al. Osimertinib activity in patients (pts) with leptomeningeal (LM) disease from non-small cell lung cancer (NSCLC): updated results from BLOOM, a Phase Ⅰ study[J]. J Clin Oncol, 2016, 34(suppl): abstr 9002. http://abstracts.asco.org/176/AbstView_176_169604.html
[30] Ahn MJ, Kim DW, Kim TM, et al. PhaseⅠstudy of AZD3759, a CNS penetrable EGFR inhibitor, for the treatment of non-small-cell lung cancer (NSCLC) with brain metastasis (BM) and leptomeningeal metastasis (LM)[J]. J Clin Oncol, 2016, 34(15 suppl): abstr 9003.
[31] Ercan D, Xu C, Yanagita M, et al. Reactivation of ERK signaling causes resistance to EGFR kinase inhibitors[J]. Cancer Discov, 2012, 2(10): 934-47. doi: 10.1158/2159-8290.CD-12-0103
[32] Eberlein CA, Stetson D, Markovets AA, et al. Acquired Resistance to the Mutant-Selective EGFR Inhibitor AZD9291 Is Associated with Increased Dependence on RAS Signaling in Preclinical Models[J]. Cancer Res, 2015, 75(12): 2489-500. doi: 10.1158/0008-5472.CAN-14-3167
[33] Tan CS, Cho BC, Soo RA. Next-generation epidermal growth factor receptor tyrosine kinase inhibitors in epidermal growth factor receptor-mutant non-small cell lung cancer[J]. Lung Cancer, 2016, 93: 59-68. doi: 10.1016/j.lungcan.2016.01.003
[34] Jia Y, Yun CH, Park E, et al. Overcoming EGFR (T790M) and EGFR (C797S) resistance with mutant-selective allosteric inhibitors[J]. Nature, 2016, 534(7605): 129-32. doi: 10.1038/nature17960
计量
- 文章访问数: 2127
- HTML全文浏览量: 390
- PDF下载量: 4653
下载:
